CU23412A3 - Diagnóstico y tratamiento de enfermedades utilizando anticuerpos anti-anti-receptor de células t vbeta o péptidos que son reconocidos por dichos anticuerpos, y proteína reguladora de la secreción endocrina 1 (prse1) - Google Patents

Diagnóstico y tratamiento de enfermedades utilizando anticuerpos anti-anti-receptor de células t vbeta o péptidos que son reconocidos por dichos anticuerpos, y proteína reguladora de la secreción endocrina 1 (prse1)

Info

Publication number
CU23412A3
CU23412A3 CU20000009A CU20000009A CU23412A3 CU 23412 A3 CU23412 A3 CU 23412A3 CU 20000009 A CU20000009 A CU 20000009A CU 20000009 A CU20000009 A CU 20000009A CU 23412 A3 CU23412 A3 CU 23412A3
Authority
CU
Cuba
Prior art keywords
antibodies
diseases
cells
prse1
vbeta
Prior art date
Application number
CU20000009A
Other languages
English (en)
Inventor
Arpi Matossian-Rogers
Original Assignee
Arpi Matossian-Rogers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9715281A external-priority patent/GB2327423B/en
Priority claimed from GBGB9810676.8A external-priority patent/GB9810676D0/en
Application filed by Arpi Matossian-Rogers filed Critical Arpi Matossian-Rogers
Publication of CU23412A3 publication Critical patent/CU23412A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales y policlonales que reconocen moléculas en células secretorias de varios tejidos blanco de enfermedades autoinmunitarias, permitiendo de esta manera un método unificado para prevenir y tratar enfermedades autoinmunitarias y otros trastornos en donde están involucradas la regulación alterada hormonal, la hiperinsulinemia y la resistencia a la insulina. También proporciona un método para detectar anticuerpos similares en suero humano u otros fluidos corporales, el cual se puede utilizar en el desarrollo de paquetes para diagnóstico. Los métodos de tratamiento que surgen de la presente invención, comprenden la administración de preparaciones de los anticuerpos, sus moleculas blanco y vectores que codifican para secuencias de los anticuerpos y sus moléculas blanco.
CU20000009A 1997-07-21 2000-01-18 Diagnóstico y tratamiento de enfermedades utilizando anticuerpos anti-anti-receptor de células t vbeta o péptidos que son reconocidos por dichos anticuerpos, y proteína reguladora de la secreción endocrina 1 (prse1) CU23412A3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
GBGB9810676.8A GB9810676D0 (en) 1998-05-18 1998-05-18 Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis

Publications (1)

Publication Number Publication Date
CU23412A3 true CU23412A3 (es) 2009-09-08

Family

ID=26311906

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000009A CU23412A3 (es) 1997-07-21 2000-01-18 Diagnóstico y tratamiento de enfermedades utilizando anticuerpos anti-anti-receptor de células t vbeta o péptidos que son reconocidos por dichos anticuerpos, y proteína reguladora de la secreción endocrina 1 (prse1)

Country Status (21)

Country Link
US (2) US6689359B1 (es)
EP (2) EP1595951A1 (es)
JP (1) JP2002511765A (es)
KR (2) KR100670070B1 (es)
CN (1) CN1330754C (es)
AT (1) ATE297983T1 (es)
AU (1) AU758455B2 (es)
BR (1) BR9810118A (es)
CA (1) CA2296842C (es)
CU (1) CU23412A3 (es)
DE (1) DE69830588T2 (es)
DK (1) DK0998556T3 (es)
EA (1) EA003131B1 (es)
ES (1) ES2245034T3 (es)
IL (3) IL133277A0 (es)
NZ (1) NZ501424A (es)
PL (1) PL204503B1 (es)
PT (1) PT998556E (es)
SI (1) SI0998556T1 (es)
TR (1) TR200000181T2 (es)
WO (1) WO1999005175A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218506A1 (en) * 1999-09-23 2002-07-03 Rigel Pharmaceuticals, Inc. Traf4 associated cell cycle proteins, compositions and methods of use
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0614366A2 (pt) 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
RU2616281C2 (ru) * 2011-09-29 2017-04-13 СЕЛЛСНЭП, ЭлЭлСи Композиции и способы испытаний на токсикогенность

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
CA2101065A1 (en) * 1991-01-22 1992-07-23 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5891623A (en) * 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
NZ501424A (en) 2005-08-26
DK0998556T3 (da) 2005-10-17
JP2002511765A (ja) 2002-04-16
CA2296842C (en) 2012-03-20
KR100567277B1 (ko) 2006-04-05
EA003131B1 (ru) 2003-02-27
TR200000181T2 (tr) 2000-05-22
IL176076A0 (en) 2006-10-05
DE69830588T2 (de) 2006-05-04
AU758455B2 (en) 2003-03-20
IL133277A0 (en) 2001-04-30
PL204503B1 (pl) 2010-01-29
KR20050046825A (ko) 2005-05-18
DE69830588D1 (de) 2005-07-21
IL133277A (en) 2006-09-05
KR100670070B1 (ko) 2007-01-19
PT998556E (pt) 2005-09-30
ATE297983T1 (de) 2005-07-15
KR20010022063A (ko) 2001-03-15
CA2296842A1 (en) 1999-02-04
WO1999005175A3 (en) 1999-06-10
AU8451798A (en) 1999-02-16
EA200000146A1 (ru) 2000-10-30
SI0998556T1 (en) 2005-10-31
EP1595951A1 (en) 2005-11-16
WO1999005175A2 (en) 1999-02-04
EP0998556B1 (en) 2005-06-15
US20050100541A1 (en) 2005-05-12
ES2245034T3 (es) 2005-12-16
CN1264426A (zh) 2000-08-23
US6689359B1 (en) 2004-02-10
BR9810118A (pt) 2000-08-08
IL176076A (en) 2010-06-16
PL338449A1 (en) 2000-11-06
CN1330754C (zh) 2007-08-08
EP0998556A2 (en) 2000-05-10

Similar Documents

Publication Publication Date Title
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
CA2266325A1 (en) A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
DK0618968T3 (da) Midler til diagnostisering og behandling af Alzheimer's sygdom
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
MX9801687A (es) Compuestos y metodos para el diagnostico de tuberculosis.
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
BR9608558A (pt) Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução
IL209115A0 (en) Pharmaceutical compositions and vaccines comprising an antigenic portion of a chlamydia protein, and uses thereof
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
NO960858L (no) Anvendelser av myelin - oligodendrocyt-glykoprotein og peptid-deler derav i metoder i forbindelse med autoimmunsykdom
Williams et al. Oral filament proteins and their regulation in Tetrahymena pyriformis
WO1992021697A3 (en) Diagnostic peptides derived from m.tuberculosis antigens
NO962596L (no) Nytt tumorsupressorgen

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)